Rocket Pharmaceuticals, Inc.
RCKT
$3.47
$0.133.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.36% | -40.04% | -42.05% | -32.31% | -8.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.67% | -24.66% | -29.77% | -24.49% | -8.19% |
| Operating Income | 30.67% | 24.66% | 29.77% | 24.49% | 8.19% |
| Income Before Tax | 291.29% | 22.40% | 29.49% | 24.56% | 1.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 278.78% | 22.40% | 29.49% | 24.56% | 1.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 278.78% | 22.40% | 29.49% | 24.56% | 1.04% |
| EBIT | 30.67% | 24.66% | 29.77% | 24.49% | 8.19% |
| EBITDA | 31.15% | 24.49% | 30.69% | 26.64% | 8.75% |
| EPS Basic | 275.89% | 23.82% | 38.48% | 36.34% | 16.44% |
| Normalized Basic EPS | 31.58% | 24.54% | 37.88% | 35.77% | 20.53% |
| EPS Diluted | 273.97% | 23.82% | 38.48% | 36.34% | 16.44% |
| Normalized Diluted EPS | 32.58% | 24.54% | 37.88% | 35.77% | 20.53% |
| Average Basic Shares Outstanding | 1.64% | 1.85% | 14.62% | 18.49% | 18.43% |
| Average Diluted Shares Outstanding | 3.15% | 1.85% | 14.62% | 18.49% | 18.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |